These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 16574455)

  • 21. Drug interactions. Kaletra and atazanavir.
    TreatmentUpdate; 2006; 18(3):7-8. PubMed ID: 17211919
    [No Abstract]   [Full Text] [Related]  

  • 22. Drug interactions. Kaletra and ezetimibe.
    TreatmentUpdate; 2006; 18(3):8. PubMed ID: 17209242
    [No Abstract]   [Full Text] [Related]  

  • 23. Good response to lopinavir/ritonavir-containing antiretroviral regimens in antiretroviral-naive HIV-2-infected patients.
    Bénard A; Damond F; Campa P; Peytavin G; Descamps D; Lascoux-Combes C; Taieb A; Simon F; Autran B; Brun-Vézinet F; Chêne G; Matheron S;
    AIDS; 2009 Jun; 23(9):1171-3. PubMed ID: 19349850
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial.
    Soriano V; García-Gasco P; Vispo E; Ruiz-Sancho A; Blanco F; Martín-Carbonero L; Rodríguez-Novoa S; Morello J; de Mendoza C; Rivas P; Barreiro P; González-Lahoz J
    J Antimicrob Chemother; 2008 Jan; 61(1):200-5. PubMed ID: 17999977
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lopinavir plus ritonavir: a novel protease inhibitor combination for HIV infections.
    Tan D; Walmsley S
    Expert Rev Anti Infect Ther; 2007 Feb; 5(1):13-28. PubMed ID: 17266450
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical experience with the combined use of lopinavir/ritonavir and rifampicin.
    L'homme RF; Nijland HM; Gras L; Aarnoutse RE; van Crevel R; Boeree M; Brinkman K; Prins JM; Juttmann JR; Burger DM
    AIDS; 2009 Apr; 23(7):863-5. PubMed ID: 19352137
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lopinavir/ritonavir- and indinavir-induced thrombocytopenia in a patient with HIV infection.
    Colebunders R; De Schacht C; Vanwolleghem T; Callens S
    Int J Infect Dis; 2004 Sep; 8(5):315-6. PubMed ID: 15325601
    [No Abstract]   [Full Text] [Related]  

  • 28. Lopinavir + ritonavir oral solution: dangerous form for newborns.
    Prescrire Int; 2011 Oct; 20(120):237. PubMed ID: 21970085
    [No Abstract]   [Full Text] [Related]  

  • 29. Monoboosted lopinavir/ritonavir as simplified second-line maintenance therapy in virologically suppressed children.
    Bunupuradah T; Kosalaraksa P; Puthanakit T; Mengthaisong T; Wongsabut J; Lumbiganon P; Phanuphak P; Burger D; Pancharoen C; Ananworanich J;
    AIDS; 2011 Jan; 25(3):315-23. PubMed ID: 21157298
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term safety and effectiveness of ritonavir, nelfinavir, and lopinavir/ritonavir in antiretroviral-experienced HIV-infected children.
    Rudin C; Burri M; Shen Y; Rode R; Nadal D; ;
    Pediatr Infect Dis J; 2008 May; 27(5):431-7. PubMed ID: 18382386
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drug interactions. Amprenavir with low-dose ritonavir.
    TreatmentUpdate; 2006; 18(3):9-10. PubMed ID: 17211921
    [No Abstract]   [Full Text] [Related]  

  • 32. Stavudine-induced pancreatitis followed by lopinavir-ritonavir-induced pancreatitis.
    Anand H; Parthasarathi G; Ramesh M
    J Postgrad Med; 2008; 54(2):153-5. PubMed ID: 18480538
    [No Abstract]   [Full Text] [Related]  

  • 33. Focus on hepatitis. Low rate of liver problems seen with LPV/r.
    Carter M
    IAPAC Mon; 2005 Oct; 11(10):325. PubMed ID: 16673499
    [No Abstract]   [Full Text] [Related]  

  • 34. [Kaletra (lopinavir/ritonavir--a new HIV protease inhibitor].
    Ershov FI; Kas'ianova NV; Vasil'ev AN
    Antibiot Khimioter; 2002; 47(11):27-9. PubMed ID: 12698577
    [No Abstract]   [Full Text] [Related]  

  • 35. CYP3A5 genotype has no impact on plasma trough concentrations of lopinavir and ritonavir in HIV-infected subjects.
    Estrela RC; Santoro AB; Barroso PF; Tuyama M; Suarez-Kurtz G
    Clin Pharmacol Ther; 2008 Aug; 84(2):205-7. PubMed ID: 18288082
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lopinavir/ritonavir dosage form affects quality of life during monotherapy in HIV-positive adults.
    Yeh RF; Lipman BA; Mayberry C; Miguel B; Nemecek JJ; Gathe JC
    J Int Assoc Physicians AIDS Care (Chic); 2010; 9(5):273-7. PubMed ID: 20841439
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term follow-up of 414 HIV-infected Romanian children and adolescents receiving lopinavir/ritonavir-containing highly active antiretroviral therapy.
    Kline MW; Rugina S; Ilie M; Matusa RF; Schweitzer AM; Calles NR; Schwarzwald HL
    Pediatrics; 2007 May; 119(5):e1116-20. PubMed ID: 17420261
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Carbamazepine toxicity induced by lopinavir/ritonavir and nelfinavir.
    Bates DE; Herman RJ
    Ann Pharmacother; 2006 Jun; 40(6):1190-5. PubMed ID: 16720703
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Potential hazard of pharmacokinetic interactions between lopinavir-ritonavir protease inhibitors and irinotecan.
    Corona G; Vaccher E; Cattarossi G; Sartor I; Toffoli G
    AIDS; 2005 Nov; 19(17):2043-4. PubMed ID: 16260915
    [No Abstract]   [Full Text] [Related]  

  • 40. A king in the CASTLE? Optimum initial HIV protease inhibitor.
    Torti C; Frank I
    Lancet; 2008 Aug; 372(9639):604-6. PubMed ID: 18722849
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.